Key Highlights
- Humana (NYSE:HUM) dropped 12.98% on November 18, 2026 to become the weakest S&P 500 stock, while UnitedHealth's 10.21% fall was the largest single drag on a Dow that shed 561.25 points.
- CMS suggested applying audit error rates across whole Medicare Advantage contracts, reaching back to 2018 payments, with recoveries estimated at approximately USD 90.2 billion for 2027 to 2036.
- Centene gave up 7.03%, Elevance Health 7.63% and agilon health roughly 21%, whereas the health care sector as a whole shed 2.20%.
- Federal Register publication is scheduled for November 19 and comments are due January 19, 2027, so the final version could still differ from this draft.
1. Humana (NYSE:HUM)
Humana (NYSE:HUM) faces the greatest exposure among the five because the bulk of its Revenue flows from government health plans. Compared with diversified rivals that have big commercial, pharmacy or services units, it has few other Earnings to cushion a squeeze on Medicare Advantage margins. The shares dropped 12.98% on November 18 following a 3.88% slide the day before, a combined loss near 16% that made it the weakest name in the S&P 500. The proposal focuses on risk adjustment data validation audits, which test whether the diagnoses that lift a plan's payments are supported by medical charts. Today repayments rest on the charts actually sampled. Under the plan, the error rate found in a sample would be extended to the entire contract, a step that can enlarge what is owed, and it would look back to 2018. Humana has long objected to extrapolation and joined challenges to the earlier 2023 rule, which a Texas federal court threw out on procedural grounds. What is different this time is the backdrop: the proposal lands while insurers already wrestle with elevated medical spending and tighter Medicare rates, leaving little slack to absorb repayments. Investors are asking Humana to size its exposure and to say whether 2027 plan pricing or benefits will change. Until it does, the shares are likely to react to every announcement out of Washington.
2. UnitedHealth (NYSE:UNH)
UnitedHealth (NYSE:UNH) operates the biggest Medicare Advantage Franchise in the country, which places it second on this list despite a more varied business. UnitedHealth's stock slid 10.21% on November 18, following a 5.42% decline the day before, for a combined drop of around 15%. Since the Dow is weighted by price, UnitedHealth was responsible for much of the index's 561.25 point decline to 50,198.17, whereas the Nasdaq Composite gained 0.42%. The threat has two parts. The company could be asked to return past payments if the rule is finalised, and future margins could narrow if plans must change how they record patient conditions. Investors worry that repayments might weigh on profit for several years, even though the measure is still only a proposal. Shareholders who rely on the Dividend want to know whether the company can maintain its dividend and buyback plans. The shares have sunk to some of their lowest levels in several years, a sharp Reversal for a stock long seen as defensive. Leveraged products built to deliver twice UnitedHealth's daily return dropped about 20%, adding to the selling. If the final rule is milder, buyers could come back quickly, although insurers are expected to push back, saying extrapolation is unfair unless coding errors in traditional Medicare are also netted off, a point that surfaced in previous litigation.
3. agilon health (NYSE:AGL)
On November 18, agilon health (NYSE:AGL) slid roughly 21% to trade near USD 115; it sits third on the list because its Business model depends on Medicare Advantage Economics despite not insuring anyone. The company works with primary care physicians to run Medicare Advantage patients under value-based agreements, sharing in both savings and losses on their medical costs. No company-specific news explaining the slide turned up, so the connection to the proposal is an inference drawn from timing and business exposure. Smaller payments to insurers could eventually tighten the money available to provider partners such as agilon. The decline came despite a reasonably good recent report: third quarter adjusted earnings of USD 1.97 a share beat an expected loss, revenue reached USD 1.51 billion, and the 2026 adjusted EBITDA outlook was raised to USD 145 million to USD 155 million. Its elevated share price for a company of this size reflects a 1-for-25 reverse split effective March 30, 2026. On November 18 an analyst kept a hold rating with a USD 112 target, near where the shares were trading. The open questions are how agilon's insurer contracts divide any recovered payments and whether rates paid to providers come under pressure. Until more clarity emerges, the shares are likely to track the insurers' moves.
4. Elevance Health (NYSE:ELV)
Because a sizeable commercial and Medicaid book cushions it, Elevance Health (NYSE:ELV) fell less than Humana or UnitedHealth, dropping 7.63% on November 18. It ranks fourth because its Medicare Advantage membership has grown in recent years, which heightens its sensitivity to the proposal. Each insurer's decline loosely followed how much it depends on Medicare Advantage compared with its other operations, and the breadth of the selling indicated that investors view the proposal as an industry-wide question rather than a problem for one or two names. Many investors had already reduced managed care exposure this year over rising medical costs, so some of the risk may have been priced in earlier this week. Still, a loss of this scale across two sessions indicates the market had not fully priced in the proposal. Rates add another obstacle. With the 10-year Treasury Yield close to 5.07% and Fed minutes showing nearly every official expects further hikes, defensive sectors like health care compete with higher bond yields for income-seeking investors. Insurers have not yet put a figure on how much of the USD 90.2 billion they could owe, and those estimates will drive valuations. Corporate comments and industry remarks in the coming weeks are the next signposts for the shares.
5. Centene (NYSE:CNC)
Centene (NYSE:CNC) lost 7.03% on November 18, placing it fifth, because its Medicare book is smaller than the Medicaid and marketplace operations. That mix leaves it less directly exposed to the audit proposal than Humana or UnitedHealth, although the fall shows investors were not sparing any large insurer. CVS Health, the parent of Aetna, dropped 5.20%, a decline softened by its pharmacy and benefit management arms, while Molina Healthcare was about 4.97% lower in the afternoon. Among the 11 S&P 500 sectors, health care posted the second largest one-day decline, 2.20%, behind only energy. Centene's immediate issue is how the market prices a company whose core programmes rely on government funding while Washington pushes for tighter payment controls. CMS is seeking to reinstate clauses a Texas federal court struck down in a 2023 rule, which makes new litigation plausible given that background. Possible outcomes run from a narrower look-back period to an allowance for coding errors in traditional Medicare. More than half of eligible beneficiaries are enrolled in Medicare Advantage, and legislators on both sides of the aisle have voters who rely on these plans, a Factor that could temper the final text. Until exposure estimates appear, Centene will likely follow the wider managed care group instead of its own earnings.
Where Things Stand
Of the five Medicare Advantage stocks, Humana carries the most exposure to the CMS audit rule because it depends most heavily on government plans. UnitedHealth runs the largest Medicare Advantage book, agilon health's fortunes track those of its provider partners, while Elevance Health and Centene report more evenly spread businesses. Comments are due January 19, 2027.






Please wait processing your request...